Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Wyeth Manufacturing Capacity Serves As Lure For Biotech Deals, Essner Says

  • News

Executive Summary

Wyeth's manufacturing capacity makes it an attractive partner for biotech products, Wyeth CEO Robert Essner said at Morgan Stanley's Pharmaceutical CEOs Unplugged conference in New York City

You may also be interested in...



Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys

Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3

Spreading The Risk: Wyeth Seeks Many Partnerships, Rather Than A Few Buys

Wyeth is focusing on reaching partnering deals for early stage agents rather than acquisitions to mitigate the high risk associated with such compounds, CEO Robert Essner said Jan. 3

GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements

GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated

Table

View full table

Tags:
Latest Headlines

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

See All
UsernamePublicRestriction

Register

PS046771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By